Immune Design Corp. (NASDAQ:IMDZ)’s share price was up 3.1% during mid-day trading on Monday . The company traded as high as $7.12 and last traded at $7.05, with a volume of 55,567 shares. The stock had previously closed at $6.84.

A number of equities analysts have recently issued reports on IMDZ shares. Wells Fargo & Co. restated a “buy” rating on shares of Immune Design Corp. in a research report on Wednesday, May 11th. Leerink Swann restated a “buy” rating on shares of Immune Design Corp. in a research report on Friday, June 10th. Zacks Investment Research downgraded Immune Design Corp. from a “buy” rating to a “hold” rating in a research report on Friday, May 13th. Jefferies Group reiterated a “buy” rating and issued a $17.00 target price (down from $20.00) on shares of Immune Design Corp. in a report on Wednesday, August 10th. Finally, Cowen and Company reiterated a “buy” rating on shares of Immune Design Corp. in a report on Wednesday, May 11th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $14.50.

The firm has a 50 day moving average price of $7.41 and a 200 day moving average price of $10.73. The firm’s market capitalization is $142.64 million.

Immune Design Corp. (NASDAQ:IMDZ) last announced its earnings results on Tuesday, August 9th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by $0.03. Analysts anticipate that Immune Design Corp. will post ($2.70) EPS for the current year.

An institutional investor recently raised its position in Immune Design Corp. stock. RS Investment Management Co. LLC boosted its position in Immune Design Corp. (NASDAQ:IMDZ) by 12.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,108,576 shares of the company’s stock after buying an additional 122,910 shares during the period. RS Investment Management Co. LLC owned approximately 5.50% of Immune Design Corp. worth $22,260,000 at the end of the most recent quarter.

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.